Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027819 (neuroblastoma)
 27,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tetanus toxin (TT) was used as a diagnostic marker for human neuroblastoma (NB) cells. TT binding sites visualized by TT and FITC-conjugated anti-TT antibodies were present on NB cells from all 13 cases studied comprising Stages II, III, IV, IVS and histologic grades 1 through 3. NB cells from both bone marrow aspirates and tumor biopsies as well as cultured NB cells were TT-positive. Diagnosis of NB was further ascertained by electron microscopy, cell culture, and quantitative determinations of catecholamines in tumor material. Only electron microscopic diagnoses had an accuracy comparable to that of TT labeling. None of the non-NB tumors (Ewing's sarcoma, acute lymphatic and myeloic leukemia, acute monocyte leukemia, chronic myeloic leukemia, Hodgkin's disease, oat cell carcinoma of the lung, pheochromocytoma), except for the pheochromocytoma, were found to bind TT specifically. These results suggest that TT may be profitably employed as a diagnostic marker of human NB cells. The advantages of the methods are its high discriminative capacity against non-NB cells and rapid applicability.
 ...
PMID:Tetanus toxin labeling as a novel rapid and highly specific tool in human neuroblastoma differential diagnosis. 400 7

To identify risk factors associated with the development of diabetes mellitus and to describe the prevalence of diabetes in pediatric hematopoietic cell transplant (HCT) survivors. The follow-up records of 748 patients who survived for at least 2 years after pediatric HCT were retrospectively reviewed for diagnosis of diabetes. Risk factors for type 2 diabetes were analyzed using multivariate statistics. Among 748 patients with a median of 11 years of follow-up, 38 developed diabetes after HCT. Four patients (three leukemia and one neuroblastoma) developed type 1 diabetes 8 to 14 years after HCT, at between 10 and 19 years of age. Thirty-four patients (32 leukemia and 2 aplastic anemia) developed type 2 diabetes 1 to 24 years after HCT, at between 11 and 41 years of age. Of the 34 patients with type 2 diabetes, 23 were non-Hispanic white, 3 had experienced asparaginase toxicity (hyperglycemia and/or pancreatitis), and 26 had a family history of diabetes. Risk factors associated with type 2 diabetes were diagnosis of acute or chronic leukemia, race/ethnicity other than non-Hispanic white, family history of diabetes, and asparaginase toxicity. The prevalence of type 1 diabetes among all surviving patients was 0.52%, or three times higher than the general U.S. population. The prevalence of type 2 diabetes was 9% among leukemia survivors and 2% among aplastic anemia survivors, both higher than expected. Pediatric HCT survivors are more likely to develop diabetes than the general population.
 ...
PMID:Diabetes mellitus in long-term survivors of pediatric hematopoietic cell transplantation. 1476 93

This study summarizes the development and progress of the pediatric Hematopoietic Stem Cell Transplantation (HSCT) program in Puerto Rico. Data from the two pediatric transplant centers was collected from July 1994 through December 2009. Overall, in the last 15 years 97 transplants have been performed to 87 children and young adults. These included 55 males and 32 females, aged between 1 and 38 years of age. The diagnosis included: acute leukemia, chronic leukemia, myelodysplasia, aplastic anemia, histiocytosis, neuroblastoma, lymphomas, PNET, Wilms tumor, and desmoplastic round cell tumor. Sources of hematopoietic stem cells for transplantation included: 5 autologous bone marrow, 23 allogeneic bone marrow using HLA matched sibling; 18 allogeneic peripheral blood stem cell (PBSC) using HLA-matched sibling and one syngeneic PBSC; 4 haploidentical T-cell depleted bone marrow transplant and 47 autologous PBSC. The results in the past 15 years are encouraging and conform that HSCT is a valuable treatment option in our pediatric population to no other alternative therapy. Our experience compares to those published by others with a 15-year overall survival of 48%. In this same group, the transplant related mortality was 14.9% comparable to published experience in Europe and USA.
 ...
PMID:Pediatric hematopoietic stem cell transplantation: fifteen year experience in Puerto Rico. 2388 68